Thrombin Receptor protease- Activated receptor 4 is a key regulator of exaggerated intimal thickening in diabetes mellitus

Circulation

Volumn 130, Issue 19, 2014, Pages 1700-1711

  Pavic, Goran ^a   Grandoch, Maria ^a   Dangwal, Seema ^b   Jobi, Klaus ^a   Rauch, Bernhard H ^c   Doller, Anke ^d   Oberhuber, Alexander ^e   Akhyari, Payam ^f   Schrör, Karsten ^a   Fischer, Jens W ^a   Fender, Anke C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e Klinik für Gefäß und Endovaskularchirurgie   (Germany)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Diabetes mellitus; Prostaglandins; Remodeling; Thrombin

Indexed keywords

ANGIOTENSIN II; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLUCOSE; MESSENGER RNA; PROTEINASE ACTIVATED RECEPTOR 4; STREPTOZOCIN; THROMBIN RECEPTOR; APOPTOSIS REGULATORY PROTEIN; GLUCOSE BLOOD LEVEL; PROSTATE APOPTOSIS RESPONSE-4 PROTEIN; THROMBIN;

ANIMAL EXPERIMENT; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHERECTOMY; CAROTID ARTERY LIGATION; CAROTID ENDARTERECTOMY; CELL PROLIFERATION; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HYPERGLYCEMIA; HYPERPLASIA; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAPHENOUS VEIN; UPREGULATION; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CAROTID ARTERY INJURY; CELL CULTURE; COMPLICATION; CYTOLOGY; DIABETIC ANGIOPATHIES; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; INTIMA; LIGATION; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; THROMBOPHILIA; VASCULAR SMOOTH MUSCLE;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; ATHERECTOMY; BLOOD GLUCOSE; CAROTID ARTERY INJURIES; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYPERGLYCEMIA; LIGATION; MALE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; SAPHENOUS VEIN; THROMBIN; THROMBOPHILIA; TUNICA INTIMA;

EID: 84913570652     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.007590     Document Type: Article

References (36)

1. Stone KE, Chiquette E, Chilton RJ. Diabetic endovascular disease: Role of coronary artery revascularization. Am J Cardiol. 2007;99:105B-112B.
2. Carr ME. Diabetes mellitus: A hypercoagulable state. J Diabetes Complications. 2001;15:44-54.
3. Robertson L, Ghouri MA, Kovacs F. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev. 2012;(8):CD002071.
4. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Metaanalysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110:453-460.
5. Ahn HS, Chackalamannil S, Boykow G, Graziano MP, Foster C. Development of proteinase- Activated receptor 1 antagonists as therapeutic agents for thrombosis, restenosis and inflammatory diseases. Curr Pharm Des. 2003;9:2349-2365.
6. de Souza Brito, F, Tricoci P. Novel anti-platelet agents: focus on thrombin receptor antagonists. J Cardiovasc Transl Res. 2013;6:415-424.
7. Coughlin SR. Thrombin signalling and protease- Activated receptors. Nature. 2000;407:258-264.
8. Shapiro MJ, Weiss EJ, Faruqi TR, Coughlin SR. Protease- Activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. J Biol Chem. 2000;275:25216-25221.
9. Kogushi M, Matsuoka T, Kuramochi H, Murakami K, Kawata T, Kimura A, Chiba K, Musha T, Suzuki S, Kawahara T, Kajiwara A, Hishinuma I. Oral administration of the thrombin receptor antagonist E5555 (atopaxar) attenuates intimal thickening following balloon injury in rats. Eur J Pharmacol. 2011;666:158-164.
10. Derian CK, Maryanoff BE, Zhang HC, Andrade-Gordon P. Therapeutic potential of protease- Activated receptor-1 antagonists. Expert Opin Investig Drugs. 2003;12:209-221.
11. Andrade-Gordon P, Derian CK, Maryanoff BE, Zhang HC, Addo MF, Cheung Wm, Damiano BP, D'Andrea MR, Darrow AL, de Garavilla L, Eckardt AJ, Giardino EC, Haertlein BJ, McComsey DF. Administration of a potent antagonist of protease- Activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther. 2001;298:34-42.
12. Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL; J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators. Double-blind, placebo-controlled Phase II studies of the protease- Activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J. 2010;31:2601-2613.
13. O'Donoghue ML, Bhatt DL, Wiviott SD, Goodman SG, Fitzgerald DJ, Angiolillo DJ, Goto S, Montalescot G, Zeymer U, Aylward PE, Guetta V, Dudek D, Ziecina R, Contant CF, Flather MD; LANCELOT-ACS Investigators. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: The lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation. 2011;123:1843-1853.
14. Lee M, Saver JL, Hong KS, Wu HC, Ovbiagele B. Risk of intracranial hemorrhage with protease- Activated receptor-1 antagonists. Stroke. 2012;43:3189-3195.
15. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. Nature. 2000;404:609-613.
16. Bretschneider E, Kaufmann R, Braun M, Nowak G, Glusa E, Schrör K. Evidence for functionally active protease- Activated receptor-4 (PAR-4) in human vascular smooth muscle cells. Br J Pharmacol. 2001;132:1441-1446.
17. Dangwal S, Rauch BH, Gensch T, Dai L, Bretschneider E, Vogelaar CF, Schrör K, Rosenkranz AC. High glucose enhances thrombin responses via protease- Activated receptor-4 in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2011;31:624-633.
18. Stolla MC, Li D, Lu L, Woulfe DS. Enhanced platelet activity and thrombosis in a murine model of type I diabetes are partially insulin-like growth factor 1-dependent and phosphoinositide 3-kinase-dependent. J Thromb Haemost. 2013;11:919-929.
19. Doller A, Akool El-S, Huwiler A, Müller R, Radeke HH, Pfeilschifter J, Eberhardt W. Posttranslational modification of the AU-rich element binding protein HuR by protein kinase Cdelta elicits angiotensin II-induced stabilization and nuclear export of cyclooxygenase 2 mRNA. Mol Cell Biol. 2008;28:2608-2625.
20. Pullmann R Jr, Juhaszova M, López de Silanes I, Kawai T, Mazan-Mamczarz K, Halushka MK, Gorospe M. Enhanced proliferation of cultured human vascular smooth muscle cells linked to increased function of RNA-binding protein HuR. J Biol Chem. 2005;280:22819-22826.
21. Rosenkranz AC, Rauch BH, Doller A, Eberhardt W, Böhm A, Bretschneider E, Schrör K. Regulation of human vascular protease- Activated receptor-3 through mRNA stabilization and the transcription factor nuclear factor of activated T cells (NFAT). Mol Pharmacol. 2011;80:337-344.
22. Hamilton JR, Cornelissen I, Coughlin SR. Impaired hemostasis and protection against thrombosis in protease- Activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemost. 2004;2:1429-1435.
23. Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton). 2007;12:261-266.
24. Kumar A, Lindner V. Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow. Arterioscler Thromb Vasc Biol. 1997;17:2238-2244.
25. Derian CK, Damiano BP, Addo MF, Darrow AL, D'Andrea MR, Nedelman M, Zhang HC, Maryanoff BE, Andrade-Gordon P. Blockade of the thrombin receptor protease- Activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther. 2003;304:855-861.
26. Jobi K, Rauch BH, Dangwal S, Freidel K, Doller A, Eberhardt W, Fischer JW, Schrör K, Rosenkranz AC. Redox regulation of human protease- Activated receptor-2 by activated factor X. Free Radic Biol Med. 2011;51:1758-1764.
27. Misquitta CM, Iyer VR, Werstiuk ES, Grover AK. The role of 3'-untranslated region (3'-UTR) mediated mRNA stability in cardiovascular pathophysiology. Mol Cell Biochem. 2001;224:53-67.
28. Schrör K, Bretschneider E, Fischer K, Fischer JW, Pape R, Rauch BH, Rosenkranz AC, Weber AA. Thrombin receptors in vascular smooth muscle cells: function and regulation by vasodilatory prostaglandins. Thromb Haemost. 2010;103:884-890.
29. Subramanian VA, Hernandez Y, Tack-Goldman K, Grabowski EF, Weksler BB. Prostacyclin production by internal mammary artery as a factor in coronary artery bypass grafts. Surgery. 1986;100:376-383.
30. Klöss S, Srivastava R, Mülsch A. Down-regulation of soluble guanylyl cyclase expression by cyclic AMP is mediated by mRNA-stabilizing protein HuR. Mol Pharmacol. 2004;65:1440-1451.
31. Schoenberg DR, Maquat LE. Regulation of cytoplasmic mRNA decay. Nat Rev Genet. 2012;13:246-259.
32. LaJevic MD, Koduvayur SP, Caffrey V, Cohen RL, Chambers DA. Thy-1 mRNA destabilization by norepinephrine a 3' UTR cAMP responsive decay element and involves RNA binding proteins. Brain Behav Immun. 2010;24:1078-1088.
33. Shah PK. Inflammation, neointimal hyperplasia, and restenosis: As the leukocytes roll, the arteries thicken. Circulation. 2003;107:2175-2177.
34. Sasaki N, Yamashita T, Takaya T, Shinohara M, Shiraki R, Takeda M, Emoto N, Fukatsu A, Hayashi T, Ikemoto K, Nomura T, Yokoyama M, Hirata K, Kawashima S. Augmentation of vascular remodeling by uncoupled endothelial nitric oxide synthase in a mouse model of diabetes mellitus. Arterioscler Thromb Vasc Biol. 2008;28:1068-1076.
35. Hui DY. Intimal hyperplasia in murine models. Curr Drug Targets. 2008;9:251-260.
36. Chen D, Carpenter A, Abrahams J, Chambers RC, Lechler RI, McVey JH, Dorling A. Protease- Activated receptor 1 activation is necessary for monocyte chemoattractant protein 1-dependent leukocyte recruitment in vivo. J Exp Med. 2008;205:1739-1746.